Nu-Cil BioStim

Obagi Medical (WALD) presented data at the ASDS meeting showcasing progress in injectable fillers and scalp serum technology. A trial demonstrated Obagi saypha ChIQ’s non-inferiority to Juvéderm Voluma XC for midface augmentation, with high patient satisfaction. Interim data for Nu-Cil BioStim Scalp Serum indicated improved scalp health. Saypha ChIQ is under FDA review, while saypha MagIQ is approved. These advancements represent potential growth drivers for the company.